Key statistics
On Wednesday, Apellis Pharmaceuticals Inc (1JK:STU) closed at 18.79, 30.10% above the 52 week low of 14.44 set on May 16, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 18.79 |
|---|---|
| High | 18.94 |
| Low | 18.36 |
| Bid | 18.75 |
| Offer | 18.81 |
| Previous close | 18.93 |
| Average volume | 0.00 |
|---|---|
| Shares outstanding | 126.53m |
| Free float | 108.90m |
| P/E (TTM) | 76.04 |
| Market cap | 2.86bn USD |
| EPS (TTM) | 0.297 USD |
Data delayed at least 15 minutes, as of Feb 11 2026.
More ▼
- Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results
- Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
- Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
- The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
- Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
- Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years
- Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference
- Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results
- New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week
- Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results
More ▼
